PolyPid Ltd. Ordinary Shares (PYPD)
PolyPid Ltd. is a biotechnology company focused on developing and commercializing novel drug delivery and infection prevention solutions. The company utilizes its proprietary P-EDES™ (Polymer-based Endoscopic Delivery System) platform to enhance the efficacy of antimicrobial and anti-inflammatory treatments, primarily targeting surgical site infections and other serious medical conditions. Based in Israel, PolyPid aims to improve patient outcomes through innovative, locally applied therapies with a focus on safety and effectiveness.
Company News
PolyPid, a late-stage biopharma company, announced successful results from its Phase 3 SHIELD II trial for its lead product candidate D-PLEX100, which demonstrated a statistically significant reduction in surgical site infections. The company has secured additional funding of $26.7 million through the exercise of warrants, which is expected to ex...
PolyPid Ltd. (PYPD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Shares of Applied Therapeutics, Inc. (NASDAQ: APLT) shares fell sharply during Friday’s session after the company released topline results of the ARISE-HF Phase 3 trial of AT-001 (caficrestat) in patients with Diabetic Cardiomyopathy (DbCM) at high risk of progression to overt heart failure. The study's primary endpoint was stabilization or i...
Biotech penny stocks to watch as stock market crash continues today. The post Best Penny Stocks To Buy Now? 3 To Watch As Stock Market Crash Continues appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.